Drug-polymer solubility

  • 文章类型: Journal Article
    分子相互作用对于稳定无定形固体分散体(ASD)中的无定形药物至关重要。大多数聚合物,然而,与药物形成强分子相互作用的能力有限。为适应要掺入的药物分子的物理化学性质而定制的聚合物,例如,通过允许结合特定的官能团,在这方面将是非常需要的。为此,新型烯丙基封端的聚合物甲氧基(聚乙二醇)-嵌段-聚(茉莉内酯)(mPEG-b-PJL)已被合成并官能化以潜在地增强特定的药物-聚合物相互作用。本研究调查了mPEG-b-PJL在ASD中的使用,使用卡维地洛(CAR),一种弱基础的模型药物。发现揭示了聚合物的酸性官能化形式(mPEG-b-PJL-COOH)与其非官能化对应物mPEG-b-PJL相比确实建立了与CAR的更强的分子相互作用。对形成ASD的聚合物有效性的评估表明,mPEG-b-PJL-COOH在混溶性方面优于其非官能化对应物,载药能力,和稳定性,从降低的分子迁移率推断。然而,溶出测试表明,与单独使用无定形CAR相比,使用mPEG-b-PJL-COOH的ASD并未显着改善溶出行为。尽管通过胶束形成潜在的溶解度增强。总的来说,这项研究证实了官能化聚合物在ASD配方中的潜力,而改善这些ASD的溶解性能的挑战仍然是进一步发展的领域。
    Molecular interactions are crucial to stabilize amorphous drugs in amorphous solid dispersions (ASDs). Most polymers, however, have only a limited ability to form strong molecular interactions with drugs. Polymers tailored to fit the physicochemical properties of the drug molecule to be incorporated, for instance by allowing the incorporation of specific functional groups, would be highly sought-for in this regard. For this purpose, the novel allyl-terminated polymer methoxy(polyethylene glycol)-block-poly(jasmine lactone) (mPEG-b-PJL) has been synthesized and functionalized to potentially enhance specific drug-polymer interactions. This study investigated the use of mPEG-b-PJL in ASDs, using carvedilol (CAR), a weakly basic model drug. The findings revealed that the acidic functionalized form of the polymer (mPEG-b-PJL-COOH) indeed established stronger molecular interactions with CAR compared to its non-functionalized counterpart mPEG-b-PJL. Evaluations on polymer effectiveness in forming ASDs demonstrated that mPEG-b-PJL-COOH outperformed its non-functionalized counterpart in miscibility, drug loading ability, and stability, inferred from reduced molecular mobility. However, dissolution tests indicated that ASDs with mPEG-b-PJL-COOH did not significantly improve the dissolution behaviour compared to amorphous CAR alone, despite potential solubility enhancement through micelle formation. Overall, this study confirms the potential of functionalized polymers in ASD formulations, while the challenge of improving dissolution performance in these ASDs remains an area of further development.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    在经皮药物递送应用中,均匀的药物分布和持续释放对于降低副作用非常重要。在目前的研究中,香草醛交联壳聚糖(CS)和聚乙烯醇(PVA)共混的基质型透皮系统是通过浇铸和干燥水溶液来制备的,用于局部递送恩诺沙星(ENR)药物。随后,包括形态在内的特性,化学结构,热行为,抗拉强度,交联度,重量均匀性,厚度,表征了交联前后CS-PVA共混膜的溶胀和药物释放。体外药物释放曲线显示,通过将香草醛作为交联剂掺入CS-PVA聚合物基质中,ENR的持续释放。此外,释放动力学曲线表明,所有样品的后续机制是Higuchi,共混膜中香草醛浓度的增加导致扩散机制从异常传输到Fickian扩散的变化。总的来说,获得的结果表明,所研究的香草醛交联CS-PVA基质型薄膜是透皮给药系统的潜在候选者。
    In transdermal drug delivery applications uniform drug distribution and sustained release are of great importance to decrease the side effects. In this direction in the present research, vanillin crosslinked chitosan (CS) and polyvinyl alcohol (PVA) blend based matrix-type transdermal system was prepared by casting and drying of aqueous solutions for local delivery of enrofloxacin (ENR) drug. Subsequently, the properties including the morphology, chemical structure, thermal behavior, tensile strength, crosslinking degree, weight uniformity, thickness, swelling and drug release of the CS-PVA blend films before and after crosslinking were characterized. In vitro drug release profiles showed the sustained release of ENR by the incorporation of vanillin as a crosslinker into the CS-PVA polymer matrix. Furthermore, the release kinetic profiles revealed that the followed mechanism for all samples was Higuchi and the increase of vanillin concentration in the blend films resulted in the change of diffusion mechanism from anomalous transport to Fickian diffusion. Overall, the obtained results suggest that the investigated vanillin crosslinked CS-PVA matrix-type films are potential candidates for transdermal drug delivery system.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    在制药行业,水溶性差的药物需要启用技术来增加在生物环境中的表观溶解度。无定形固体分散体(ASD)已成为一种有吸引力的策略,已用于销售20多种口服药物产品。无定形形式固有地不稳定,并且在保质期储存期间显示相分离和结晶。聚合物通过抗塑作用稳定无定形药物,降低分子迁移率,降低药物的化学潜力,并提高ASD的玻璃化转变温度。这里,药物-聚合物的混溶性是ASD物理稳定性的重要因素。本综述讨论了药物-聚合物相互作用的基础,主要关注评估药物在聚合物中的溶解度和混溶性的方法。评估药物-聚合物溶解度和混溶性的方法已被分类为热,光谱学,微观,基于固液平衡,流变学,和计算方法。热方法通常用于确定药物在聚合物中的溶解度,而其他方法提供有关药物-聚合物混溶性的定性信息。尽管取得了进步,这些方法中的大多数仍然不足以提供在室温下药物-聚合物混溶性的价值。仍然需要能够在药学相关温度下准确测定药物-聚合物混溶性的方法。
    In the pharmaceutical industry, poorly water-soluble drugs require enabling technologies to increase apparent solubility in the biological environment. Amorphous solid dispersion (ASD) has emerged as an attractive strategy that has been used to market more than 20 oral pharmaceutical products. The amorphous form is inherently unstable and exhibits phase separation and crystallization during shelf life storage. Polymers stabilize the amorphous drug by antiplasticization, reducing molecular mobility, reducing chemical potential of drug, and increasing glass transition temperature in ASD. Here, drug-polymer miscibility is an important contributor to the physical stability of ASDs. The current Review discusses the basics of drug-polymer interactions with the major focus on the methods for the evaluation of solubility and miscibility of the drug in the polymer. Methods for the evaluation of drug-polymer solubility and miscibility have been classified as thermal, spectroscopic, microscopic, solid-liquid equilibrium-based, rheological, and computational methods. Thermal methods have been commonly used to determine the solubility of the drug in the polymer, while other methods provide qualitative information about drug-polymer miscibility. Despite advancements, the majority of these methods are still inadequate to provide the value of drug-polymer miscibility at room temperature. There is still a need for methods that can accurately determine drug-polymer miscibility at pharmaceutically relevant temperatures.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号